Alex ALIPER

Alex Aliper has dedicated his career to pioneering the use of artificial intelligence (AI) in drug discovery, generative chemistry, and biology, enabling faster, more accurate identification of therapeutic candidates.

As the Co-Founder and President of Insilico Medicine, he led the development of the first AI-designed drug INS018_055, which successfully entered clinical trials for the treatment of idiopathic pulmonary fibrosis. Based on a next-generation generative AI platform, Insilico Medicine advanced ISM001-055 to the preclinical candidate stage in just 18 months, and further advanced it to Phase I clinical trials in only 9 months. Currently, the drug is undergoing Phase II clinical trials.

He has been instrumental in driving our company's “Generative AI for Sustainability” vision, which leverages AI to develop more sustainable chemicals, fuels, and materials.

While focused on AI-driven innovations, Alex has also overseen the establishment of a robotics lab at Insilico Medicine. This lab integrates AI with advanced robotics, enhancing the ability to conduct high-throughput screening and validation of drug candidates, significantly improving the efficiency and precision of our research. Currently, Insilico Medicine has over 30 pipelines, including 16 preclinical candidates and 6 that have entered clinical stages.